We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Eagle Pharmaceuticals Inc (EGRX) USD0.001

Sell:$48.61 Buy:$48.87 Change: $0.96 (2.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$48.61
Buy:$48.87
Change: $0.96 (2.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$48.61
Buy:$48.87
Change: $0.96 (2.01%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Eagle Pharmaceuticals, Inc. is an integrated pharmaceutical company. The Company takes a molecule from preclinical research through regulatory approval and into the marketplace, including development, manufacturing and commercialization. The Company identifies challenging-to-treat diseases of the central nervous system or metabolic critical care therapeutic areas, as well as in oncology. The Company offers three products: Ryanodex, dantrolene sodium) (Ryanodex), bendamustine ready-to-dilute (RTD) 500ml solution (Belrapzo), and rapidly infused bendamustine RTD (Bendeka). The Company market Ryanodex and Belrapzo, and Teva Pharmaceutical Industries Ltd. (Teva) markets Bendeka a lyophilized powder formulation of bendamustine hydrochloride in Japan.

Contact details

Address:
50 Tice Blvd Ste 315
WOODCLIFF LAKE
07677-7637
United States
Telephone:
+1 (201) 3265300
Website:
https://www.eagleus.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
EGRX
ISIN:
US2697961082
Market cap:
$615.73 million
Shares in issue:
12.91 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Scott Tarriff
    President, Chief Executive Officer, Director
  • Brian Cahill
    Chief Financial Officer
  • Michael Moran
    Principal Operating Officer
  • Judith Ng-Cashin
    Executive Vice President, Chief Medical Officer
  • David Pernock
    Executive Vice President, Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.